RxDoctor Payments Data

Laura Powell

Psychiatric/Mental Health · Nacogdoches, TXNPI 1194777276

Payments from drug & device makers

$762in general payments, 2019–2025

Across 33 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$231
  • Sunovion Pharmaceuticals Inc.$202
  • Johnson & Johnson$74
  • Catalyst Pharmaceuticals, Inc.$57
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
  • Otsuka America Pharmaceutical, Inc.$33
  • plus $118 from 5 others

What the payments were for

  • Food & beverage$63283%
  • Education$13017%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$762 in reported general payments places this provider in the 55th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$11,860
Medicare patients
42
Services billed
258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine49$233,692
AustedoDeutetrabenazine33$203,425
RexultiBrexpiprazole67$100,531
Invega TrinzaPaliperidone Palmitate12$90,752
Invega SustennaPaliperidone Palmitate35$75,616
VraylarCariprazine Hcl39$55,656
UzedyRisperidone12$31,309
AristadaAripiprazole Lauroxil15$27,673
CaplytaLumateperone Tosylate11$17,772
TrintellixVortioxetine Hydrobromide32$13,641
Divalproex Sodium ErDivalproex Sodium156$5,336
Quetiapine Fumarate309$4,346
Duloxetine Hcl196$3,794
Paliperidone ErPaliperidone30$3,699
Buspirone Hcl208$2,752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Uzedy, Loxapine$231$468,884112 claims
Johnson & JohnsonInvega Trinza, Invega Sustenna$74$166,36847 claims
Otsuka America Pharmaceutical, Inc.Rexulti$33$100,53167 claims
AbbVieVraylar$14$55,65639 claims
Alkermes, Inc.Aristada$28$27,67315 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$47$17,77211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Nacogdoches

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →